The renin-angiotensin-aldosterone system, glucose metabolism and diabetes

被引:206
作者
Giacchetti, G
Sechi, LA
Rilli, S
Carey, RM [1 ]
机构
[1] Univ Virginia, Dept Med, Div Endocrinol & Metab, Hlth Syst, Charlottesville, VA 22908 USA
[2] Univ Udine, Dipartimento Patol & Med Sperimentale & Clin, Med Clin, I-33100 Udine, Italy
[3] Univ Politecn Marche, Dept Internal Med, Div Endocrinol, I-60020 Ancona, Italy
关键词
D O I
10.1016/j.tem.2005.02.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In diabetes mellitus (DM), the circulating renin-angiotensin system (RAS) is suppressed, but the renal tissue RAS is activated. Hyperglycemia increases tissue angiotensin II (Ang II), which induces oxidative stress, endothelial damage and disease pathology including vasoconstriction, thrombosis, inflammation and vascular remodeling. In early DM, the type 1 Ang II (AT(1)) receptor is upregulated but the type 2 Ang II (AT(2)) receptor is downregulated. This imbalance can predispose the individual to tissue damage. Hyperglycemia also increases the production of aldosterone, which has an unknown contribution to tissue damage. The insulin resistance state is associated with upregulation of the AT(1) receptor and an increase in oxygen free radicals in endothelial tissue caused by activation of NAD(P)H oxidase. Treatment with an AT(1) receptor blocker normalizes oxidase activity and improves endothelial function. An understanding of the tissue renin-angiotensin-aldosterone system, which is a crucial factor in the progression of tissue damage in DM, is imperative for protection against tissue damage in this chronic disease.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 91 条
[1]  
AHANG SL, 1999, KIDNEY INT, V55, P454
[2]   Evidence that the angiotensin IV (AT4) receptor is the enzyme insulin-regulated aminopeptidase [J].
Albiston, AL ;
McDowall, SG ;
Matsacos, D ;
Sim, P ;
Clune, E ;
Mustafa, T ;
Lee, J ;
Mendelsohn, FAO ;
Simpson, RJ ;
Connolly, LM ;
Chai, SY .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (52) :48623-48626
[3]   Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy [J].
Andersen, S ;
Tarnow, L ;
Rossing, P ;
Hansen, BV ;
Parving, HH .
KIDNEY INTERNATIONAL, 2000, 57 (02) :601-606
[4]   RENAL RENIN-ANGIOTENSIN SYSTEM IN DIABETES - FUNCTIONAL, IMMUNOHISTOCHEMICAL, AND MOLECULAR BIOLOGICAL CORRELATIONS [J].
ANDERSON, S ;
JUNG, FF ;
INGELFINGER, JR .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 265 (04) :F477-F486
[5]  
[Anonymous], CHEMOSPHERE GLOBAL C, DOI DOI 10.1016/S1465-9972(99)00054-9
[6]   Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole [J].
Arima, S ;
Endo, Y ;
Yaoita, H ;
Omata, K ;
Ogawa, S ;
Tsunoda, K ;
Abe, M ;
Takeuchi, K ;
Abe, K ;
Ito, S .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) :2816-2823
[7]   Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade [J].
Awad, AS ;
Webb, RL ;
Carey, RM ;
Siragy, HM .
JOURNAL OF HYPERTENSION, 2004, 22 (08) :1571-1577
[8]   Angiotensin II type 2 receptor - Mediated vasodilation in human coronary microarteries [J].
Batenburg, WW ;
Garrelds, IM ;
Bernasconi, CC ;
Juillerat-Jeanneret, L ;
van Kats, JP ;
Saxena, PR ;
Danser, AHJ .
CIRCULATION, 2004, 109 (19) :2296-2301
[9]   Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade [J].
Bonnet, F ;
Candido, R ;
Carey, RM ;
Casley, D ;
Russo, LM ;
Osicka, TM ;
Cooper, ME ;
Cao, ZM .
JOURNAL OF HYPERTENSION, 2002, 20 (08) :1615-1624
[10]  
Bouby N, 1997, J AM SOC NEPHROL, V8, P1658